Leerink raised the firm’s price target on uniQure (QURE) to $44 from $26 and keeps an Outperform rating on the shares. The firm notes the company announced it has reached regulatory alignment on a path to accelerated approval with the FDA that will require it to run an additional study, removing the overhang on the stock for many investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target raised to $20 from $14 at RBC Capital
- Wells upgrades uniQure on ‘high likelihood of success’ in Huntington’s
- uniQure upgraded to Overweight from Equal Weight at Wells Fargo
- Oracle reports mixed Q2, Gen Digital to acquire MoneyLion: Morning Buzz
- uniQure upgraded to Strong Buy at Raymond James after FDA alignment reached